Match tumor microenvironment phenotype to therapeutic mechanism of action
We are developing a clinical trial application (CTA) using the Xerna™ TME Panel licensed from OncXerna Therapeutics, Inc. This is a novel diagnostic that uses RNA gene expression data and a machine learning algorithm to classify patients based on the dominant biologies of the tumor microenvironment (TME). The great advantage of this is that patients can be matched with therapies that directly address these biologies.
Predict patient response to immune targeted therapies
The Xerna TME Panel helps to identify the dominant biology of the TME and classify patient tumors into one of four TME subtypes:
- Angiogenic (A)
- Immune Suppressed (IS)
- Immune Active (IA)
- Immune Desert (ID)
These subtypes can be used to match the patient’s biology to the therapeutic mechanism of action and can help to predict which patients are most likely to benefit from specific immune targeted therapies.
Discover more about our collaboration with OncXerna Therapeutics and how the Xerna TME Panel can substantially improve your patients’ outcomes.
Explore the latest advances from clinical trials with the Xerna™ TME Panel
Did you know that Xerna™ TME subtype classification is now available for retrospective testing of tumor biopsies and immune status classification at QIAGEN Genomic Services?